Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05518149 · ClinicalTrials.gov registry record · Phase 3
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
A Phase 3 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 840
- Enrollment target
- 20
- Study locations
NCT05518149: Active Phase 3 study of Depressive Disorder, Major, sponsored by Janssen Research & Development.
NCT05518149 is a Phase 3 study of Depressive Disorder, Major that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 840 participants, above the 226-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (272% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05518149, a Phase 3 study of Depressive Disorder, Major, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 840 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\]) in all participants with major depressive disorder (MDD).
Primary Outcome
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have causal relationship with the intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or
Conditions Studied
Interventions
- DRUG Aticaprant
Study Locations (20)
California
- Advanced Research Center Inc - Anaheim
- Proscience Research Group - Culver City
- Behavioral Research Specialists LLC - Glendale
- Sunwise Clinical Research - Lafayette
- Asclepes Research - Long Beach
- Excell Research Inc - Oceanside
- Pacific Neuropsychiatric Specialists - Orange
- Prospective Research Innovations Inc - Rancho Cucamonga
- University of California San Diego Medical Center - San Diego
- Syrentis Clinical Research - Santa Ana
- CMB Clinical Trials - Santee
- California Neuroscience Research - Sherman Oaks
- Viking Clinical Research Ltd - Temecula
- Pacific Clinical Research Medical Group - Upland
- Next Level Clinical Trials, LLC - West Covina
Arizona
- SW Biomedical Research LLC - Tucson
- University of Arizona - Tucson
Alabama
- University of Alabama at Birmingham - The Kirklin Clinic - Birmingham
Colorado
- MCB Clinical Research Centers LLC - Colorado Springs
Connecticut
- University of Connecticut Health Center - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 840 participants |
| Start Date | 2022-09-22 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 3 |
What the registry record for NCT05518149 still lists
NCT05518149 is an interventional study that assigns participants to a tested intervention. The registered 840 participants enrollment target is mid-sized for trials with a published cap, above the 226-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (272% higher).
The record links to 1 condition, with Depressive Disorder, Major appearing as the primary indexed condition, and to 1 intervention - of which Aticaprant is the first listed.
NCT05518149 names 20 study sites across 5 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05518149 about?
NCT05518149 is a clinical study titled "A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)". The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor \[SSRI\] or serotonin and norepinephrine reuptake inhibitor \[SNRI\]) in all participants with major depre...
What is the current status of trial NCT05518149?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 840 participants. The study started on 2022-09-22. Estimated completion is 2025-04-25.
What conditions does trial NCT05518149 study?
This clinical trial studies the following conditions: Depressive Disorder, Major.
What interventions are being tested in trial NCT05518149?
The interventions under investigation include: Aticaprant (DRUG).
Who is sponsoring clinical trial NCT05518149?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05518149 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05518149's enrollment target sits among peer trials
840 2nd of 52 the highest of 52 other Depressive Disorder, Major trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Depressive Disorder, Major trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 3
-
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
RECRUITING · Phase 3
-
Psilocybin for Major Depressive Disorder (MDD)
ACTIVE NOT RECRUITING · Phase 3
-
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide
COMPLETED · Phase 3
-
A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04831580 · 840 participants · NA
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
- NCT04976881 · 840 participants · NA
Promoting Preconception Care and Diabetes Self-Management Among Reproductive-Aged Women With Diabetes
- NCT04985903 · 840 participants · NA
Baby Steps III: Testing a Clinician and Patient Intervention to Promote Smoking Cessation Among Pregnant Women
- NCT05384626 · 840 participants · Phase 1
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI